Sagar Dholariya

Abstract

Introduction: The metabolic syndrome (MetS) is a rising public-health problem and clinical challenge worldwide. Vitamin B12 deficiency is associated with MetS. But its role as independent risk factor for MetS is not clear. Objective of our study was to evaluate serum vitamin B12 levels in MetS cases and its association with parameters of MetS Material and Methods: Total 50 MetS cases and 50 age and sex matched healthy controls were included in the study. Cases were selected according to new international diabetes federation (IDF) criteria of MetS. Estimation of serum vitamin B12 were done on electrochemiluminescent machine immulite-1000 by electrochemiluminesce principle. Estimation of fasting blood sugar, triglyceride and HDL were done on advia 1800 chemistry autoanalyzer. Waist circumference was measured by measuring tape. Blood pressure was measured by sphygmomanometer. Result: The median values of vitamin B12 in cases were 210 pg/ml with the interquartile difference of 293.75 and the median value of vitamin B12 in controls were 178 pg/ml with the interquartile difference of 137.5. The differences between mean ranks of two groups were not significant (P=0.25). Vitamin B12 were found to be positively correlated with serum triglyceride (correlation coefficient 0.337; P=0.001) and serum HDL level (correlation coefficient 0.207; P= 0.039). Conclusion: There was no significant difference of serum vitamin B12 levels in metabolic syndrome patients. Serum vitamin B12 was positively correlated with serum triglyceride and HDL level. Keywords: Vitamin B12, Metabolic syndrome, Triglyceride, HDL.

View Article

Abstract

Introduction: Epithelial ovarian cancer (EOC) is most common malignancy affecting Indian women. One of the transcriptional targets of p53 is human homolog of Murine Double Minute 2 Oncogene (MDM2) which is a crucial negative regulator of p53. Polymorphism in intronic promoter P2 region of MDM2 at position 309 increase binding affinity of specific protein 1, lead to over expression of MDM2 and deflation of p53 pathway. The objectives of study were to find effect of MDM2 SNP309 T>G polymorphism and serum estrogen level on risk of development of EOC and interaction between MDM2 SNP309 T>G and TP53 72 Arg>Pro polymorphism. Materials and Methods: Eighty EOC cases and eighty age matched healthy controls were included in study. MDM2 SNP309 T>G polymorphism was detected by ASO-PCR technique and serum estrogen levels were detected by chemiluminescence immunoassay. Result: MDM2 SNP309 GG genotype was associated with significantly increased risk (OR: 2.86, 95%, CI: 1.07-7.66; P=0.03) and early age onset (P=0.001) of EOC. Serum Estrogen was significantly (PG and TP53 72Arg>Pro gene polymorphism act additively in developing ovarian cancer. Conclusion: This study provides evidence that MDM2 SNP309 T>G promoter polymorphism in association with the higher serum estrogen levels is associated with genetic susceptibility and early age onset of ovarian cancer. Keywords: Epithelial ovarian cancer, MDM2, TP53, Estrogen.

View Article